AbbVie Inc. ROA

ROA of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including ROA growth rates and interactive chart. Return on Assets (ROA) is an indicator of how well a company utilizes its assets, by determining how profitable a company is relative to its total assets. A company with $1 million in net income and $10 million in average assets will have a 10% ROA.


Highlights and Quick Summary

  • Annual ROA for 2019 was 10.62% (a 21.51% increase from previous year)
  • Annual ROA for 2018 was 8.74% (a 12.63% increase from previous year)
  • Annual ROA for 2017 was 7.76% (a -22.32% decrease from previous year)
  • Twelve month ROA ending March 30, 2020 was 11.4% (a 7.34% increase compared to previous quarter)
  • Twelve month trailing ROA increased by 64.5% year-over-year
Trailing ROA for the last four month:
30 Mar '20 30 Dec '19 29 Sep '19 29 Jun '19
11.4% 10.62% 5.18% 6.93%
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical ROA of AbbVie Inc.

Most recent ROAof ABBV including historical data for past 10 years.

Interactive Chart of ROA of AbbVie Inc.

AbbVie Inc. ROA for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 10.62%
2018 8.74%
2017 7.76%
2016 9.99%
2015 12.77%
2014 6.26%
2013 14.69%
2012 22.67%
2011 16.89%
2010 39.54%
2009 0.0%

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc., a research-based biopharmaceutical company, develops and markets pharmaceutical products in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a biologic therapy administered as an injection for autoimmune and intestinal diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, treatment of endometriosis and central precocious puberty, and for the treatment of patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; and Janssen Biotech, Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.